PMID- 12139749
OWN - NLM
STAT- MEDLINE
DCOM- 20021001
LR  - 20190705
IS  - 0007-1048 (Print)
IS  - 0007-1048 (Linking)
VI  - 118
IP  - 2
DP  - 2002 Aug
TI  - Acquired activated protein C resistance is associated with the co-existence of 
      anti-prothrombin antibodies and lupus anticoagulant activity in patients with 
      systemic lupus erythematosus.
PG  - 577-83
AB  - Venous thromboembolism (VTE) is one of the common manifestations in the 
      anti-phospholipid (aPL) syndrome. We examined the levels of IgG antibodies (Abs) 
      to beta2-glycoprotein I (beta2-GP I) and prothrombin, lupus anticoagulant (LA) 
      activity, activated protein C resistance (APC-R), and factor V Leiden in 96 
      patients with systemic lupus erythematosus (SLE); 19 with VTE and 77 without VTE. 
      Acquired APC-R, which was not found in any patient with the factor V Leiden 
      mutation, was present in 33 (34.4%) out of the 96 patients with SLE. The presence 
      of acquired APC-R was a strong risk factor for VTE. The SLE patients were divided 
      into four groups according to the results of enzyme-linked immunosorbent assay 
      (ELISA) and LA activity for each aPL Abs: ELISA+, LA+; ELISA+, LA-; ELISA-, LA+; 
      and ELISA-, LA-. A significant association was observed between APC-R and the 
      co-existence of anti-beta2-GP I Abs and LA activity or of anti-prothrombin Abs 
      and LA activity. There was no association between APC-R and the presence of 
      anti-beta2-GP I Abs, anti-prothrombin Abs, or LA activity alone. However, when 
      multivariate logistical regression analysis was performed, it was clear that only 
      the co-existence of anti-prothrombin and LA activity was a significant risk 
      factor for APC-R. These findings indicate that the co-existence of 
      anti-prothrombin Abs and LA activity may be an important factor in the 
      pathogenesis of acquired APC-R in patients with SLE.
FAU - Nojima, Junzo
AU  - Nojima J
AD  - Laboratory for Clinical Investigation, Osaka University Hospital, 2-15 Yamadaoka, 
      Suita, Osaka 565-0871, Japan. nojima@hp-lab.med.osaka-u.ac.jp
FAU - Kuratsune, Hirohiko
AU  - Kuratsune H
FAU - Suehisa, Etsuji
AU  - Suehisa E
FAU - Kawasaki, Tomio
AU  - Kawasaki T
FAU - Machii, Takashi
AU  - Machii T
FAU - Kitani, Teruo
AU  - Kitani T
FAU - Iwatani, Yoshinori
AU  - Iwatani Y
FAU - Kanakura, Yuzuru
AU  - Kanakura Y
LA  - eng
PT  - Journal Article
PL  - England
TA  - Br J Haematol
JT  - British journal of haematology
JID - 0372544
RN  - 0 (Antibodies, Antiphospholipid)
RN  - 0 (Glycoproteins)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Lupus Coagulation Inhibitor)
RN  - 0 (beta 2-Glycoprotein I)
RN  - 0 (factor V Leiden)
RN  - 9001-24-5 (Factor V)
RN  - 9001-26-7 (Prothrombin)
SB  - IM
CIN - Br J Haematol. 2003 May;121(3):527-9. PMID: 12716380
MH  - Activated Protein C Resistance/*etiology
MH  - Adult
MH  - Aged
MH  - Antibodies, Antiphospholipid/analysis
MH  - Enzyme-Linked Immunosorbent Assay/methods
MH  - Factor V
MH  - Female
MH  - Glycoproteins/immunology
MH  - Humans
MH  - Immunoglobulin G/metabolism
MH  - Lupus Coagulation Inhibitor/*physiology
MH  - Lupus Erythematosus, Systemic/*complications
MH  - Male
MH  - Middle Aged
MH  - Prothrombin/immunology
MH  - Risk Factors
MH  - Thromboembolism/*etiology
MH  - Venous Thrombosis/*etiology
MH  - beta 2-Glycoprotein I
EDAT- 2002/07/26 10:00
MHDA- 2002/10/03 04:00
CRDT- 2002/07/26 10:00
PHST- 2002/07/26 10:00 [pubmed]
PHST- 2002/10/03 04:00 [medline]
PHST- 2002/07/26 10:00 [entrez]
AID - 3642 [pii]
AID - 10.1046/j.1365-2141.2002.03642.x [doi]
PST - ppublish
SO  - Br J Haematol. 2002 Aug;118(2):577-83. doi: 10.1046/j.1365-2141.2002.03642.x.